ABBV 701
Alternative Names: ABBV-701Latest Information Update: 21 Jul 2025
At a glance
- Originator AbbVie
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 04 Apr 2025 Preclinical trials in Unspecified in USA (SC) prior to April 2025
- 25 Mar 2025 AbbVie initiates enrolment in a phase I trial for Healthy volunteers in USA (SC) (NCT06895343)